Learn more about Nevrargenics and our team on our brand new website - nevrargenics.com

Nevrargenics is pleased to announce that it is now fully active and functioning, and off on its journey to develop novel neurodegenerative disease drugs, having finally secured IP license rights from its two founding universities.

Nevrargenics is up and running with its first investment raise nicely underway and lead drug undergoing safety tox and efficacy studies. We'll keep you posted!

In the meantime, if you would like to join us on our journey to end neurodegeneration, contact [email protected], or follow this link for signing up online to invest: envestors.envestry.com/deals/00110bbb…

Thanks to the organisors of the Investor Ladder University Commercialisation Conference yesterday in Leeds (lnkd.in/e2ZC-ud2). We need more of these types events in the north! Lots of exciting new university spinouts and most importantly, investors.

Want to hear about how Nevrargenics is looking to tackle neurodegeneration? Listen to this podcast...it even tells you why Brussels Sprouts are interesting! labiotech.eu/trends-news/be…

Great to have attended the TRICALS Masterclass 2022 at the Novotel near Schiphol, Netherlands last week. Huge thanks to the organisors for the invitation and a super meeting!

Nevrargenics has a new website! Tells you what we're doing and how we're doing to help try solve the major challenge that is neurodegeneration. Check it out! We'd love to hear from you. nevrargenics.com